Exhibiting at VIV Asia 2025

Tianjin Ringpu Bio-Technology Co., Ltd.

Tianjin Ringpu Bio-Technology Co., Ltd., established in 1998 and headquartered in Tianjin, China, is a leading biotechnology company specializing in the research, development, manufacturing, and marketing of veterinary pharmaceuticals, vaccines, and feed additives. The company is publicly listed on the Shenzhen Stock Exchange (Stock Code: 300119) and has consistently demonstrated growth through innovation and strategic partnerships.

Core Business

Ringpu Bio-Technology focuses on enhancing animal health and productivity through its advanced biotechnological solutions. The company's portfolio is diversified into three major product categories:

• Vaccines: Primarily targeting poultry, livestock, and companion animals.
• Veterinary Pharmaceuticals: A broad range of antibiotics, antiparasitics, and antifungals.
• Feed Additives: Nutritional supplements including vitamin premixes and mineral supplements.

Product and Service Offerings

Ringpu Bio-Technology has established a reputation for developing high-quality, effective, and safe animal health products. Key offerings include:

Vaccines:

• SCBM H5+H7: A cutting-edge avian influenza vaccine designed to protect against both H5 and H7 subtypes, enhancing biosecurity for poultry farms.
• SCBM H5: Specialized vaccine targeting the H5 subtype of avian influenza.
• RINVAC IC: Highly effective infectious coryza vaccine designed for poultry protection.
• RINBIO Rec ND: Recombinant Newcastle disease vaccine offering superior immunity.

Veterinary Pharmaceuticals:

• Antibiotics: Comprehensive range of products for bacterial infections in livestock and poultry.
• Antiparasitics: Formulations aimed at controlling parasitic infestations in animals.
• Antifungals: Products designed to treat fungal infections in livestock and companion animals.

Feed Additives:

• Vitamin Premixes: Tailored solutions to enhance the nutritional value of feed.
• Mineral Supplements: Essential minerals to boost animal growth and immunity.

Specialization and Core USP

The company's core strength lies in its Research and Development (R&D) capabilities, backed by state-of-the-art facilities and collaborations with universities and research institutes. Ringpu Bio-Technology has over 500 R&D personnel dedicated to innovative product development, ensuring the company remains at the forefront of animal health technology.

Its specialized vaccines for avian influenza (e.g., SCBM H5+H7) are particularly valued in regions with high disease prevalence. The company also provides custom-tailored feed additives designed to improve productivity and reduce dependency on antibiotics, enhancing animal welfare and food safety.

Financials

Ringpu Bio-Technology has shown consistent growth over the years. As of the latest available financial data:

• Annual Revenue: Approximately $280 million.
• Net Profit: Roughly $45 million, reflecting strong profitability despite intense market competition.
• Market Capitalization: Estimated at over $1.2 billion.
• R&D Investment: Around 8% of annual revenue, indicating a strong commitment to innovation and quality improvement.

Shipments Data

The company actively exports its products to various countries, particularly in Southeast Asia, Africa, and South America. Notable shipment statistics include:

• Top Export Destinations: Indonesia, Thailand, Vietnam, Brazil, and South Africa.
• Number of Shipments (Annually): Over 1,500.
• Total Export Value: Approximately $100 million.

Target Market

Ringpu Bio-Technology targets a wide range of customers, including:

• Poultry and Livestock Farms: Large-scale producers seeking vaccines and veterinary pharmaceuticals to ensure animal health and productivity.
• Veterinary Clinics: Offering high-quality vaccines and medicines for companion animals.
• Feed Manufacturers: Supplying nutritional additives aimed at improving feed quality and animal growth.

Capabilities

• Research and Development: The company boasts one of the largest R&D teams in the Chinese veterinary pharmaceutical industry, with advanced laboratories and manufacturing facilities adhering to international quality standards.
• Production Capacity: Multiple GMP-certified production lines capable of producing millions of vaccine doses annually.
• Global Distribution Network: Extensive supply chain network ensuring timely delivery of products to various countries worldwide.

Certifications and Compliance

Ringpu Bio-Technology adheres to stringent quality standards and has obtained various certifications, including:

• GMP Certification: For its manufacturing facilities.
• ISO 9001: Quality Management Systems.
• ISO 14001: Environmental Management Systems.
• OIE Certification: Recognized by the World Organisation for Animal Health for its vaccine production facilities.

Customer Testimonials

• Testimonial from Poultry Farm Owner (Indonesia):
  “Since we started using Ringpu’s SCBM H5+H7 vaccine, our flock’s immunity levels have improved significantly. The customer support and guidance provided by their technical team are exceptional.”

• Testimonial from Veterinary Specialist (China):
  “Ringpu’s veterinary pharmaceuticals are reliable and highly effective. We particularly appreciate their focus on research and innovation.”

---

Ringpu Bio-Technology continues to strengthen its position in the global animal health industry by investing heavily in research and expanding its product portfolio. Its commitment to quality and safety has earned it a reputable name among veterinary professionals and livestock producers worldwide.